Invex Therapeutics Income Statement

Financials in millions AUD. Fiscal year is July - June.

Millions AUD. Fiscal year is Jul - Jun.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022	Jun '21 Jun 30, 2021
Other Revenue	0.23	0.23	1.21	0.46	0.18	-
Revenue	0.23	0.23	1.21	0.46	0.18	-
Revenue Growth (YoY)	-81.10%	-81.10%	164.06%	151.90%	-	-
Gross Profit	0.23	0.23	1.21	0.46	0.18	-
Selling, General & Admin	1.07	0.72	1.17	1.12	0.9	0.74
Research & Development	0.24	0.2	2.04	7.4	2.96	1.14
Operating Expenses	1.31	0.94	3.35	9.01	4.22	2.44
Operating Income	-1.08	-0.71	-2.13	-8.55	-4.03	-2.44
Interest & Investment Income	0.18	0.23	0.49	0.8	0.08	0.16
Other Non Operating Income (Expenses)	0.06	-	-	-	-	0
EBT Excluding Unusual Items	-0.84	-0.48	-1.64	-7.75	-3.95	-2.28
Pretax Income	-0.84	-0.48	-1.64	-7.75	-3.95	-2.28
Net Income	-0.84	-0.48	-1.64	-7.75	-3.95	-2.28
Net Income to Common	-0.84	-0.48	-1.64	-7.75	-3.95	-2.28
Shares Outstanding (Basic)	75	76	75	75	75	75
Shares Outstanding (Diluted)	75	76	75	75	75	75
Shares Change (YoY)	-0.29%	0.51%	0.19%	0.02%	0.03%	33.77%
EPS (Basic)	-0.01	-0.01	-0.02	-0.10	-0.05	-0.03
EPS (Diluted)	-0.01	-0.01	-0.02	-0.10	-0.05	-0.03
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	-
Operating Margin	-471.50%	-309.63%	-176.00%	-1861.73%	-2212.89%	-
Profit Margin	-364.90%	-208.16%	-135.43%	-1688.11%	-2169.06%	-
EBIT	-1.08	-0.71	-2.13	-8.55	-4.03	-2.44
EBIT Margin	-	-	-176.00%	-	-	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.